Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2024-03-06 00:00:00 ET · period of report 2024-03-04 · accession 0000905148-24-000911 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-06 | 2024-03-04 | ATRA | Touchon Pascal | Pres, CEO, Dir | S - Sale | $0.72 | -24.8K | 1.91M | -1% | -$17.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-04 | S | D | 24,844 | $0.72 | 1,910,652 | D | — | — | (F2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 4, 2024 and March 5, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. |